CCR2 and prostate carcinoma: To confirm that the CCL2–CCR2 axis and its downstream CCL17/22–CCR4 axis really contributed to the induction of prostate cancer cell migration, the CCL2–CCR2 or CCL17/22–CCR4 axis was blocked using a receptor antagonist.